FLT3 and acute myeloid leukemia: These results demonstrated that FT538 iPSC‐NK combinations with cytarabine, gilteritinib and venetoclax are highly effective against leukaemic cells, including FLT3‐mutated AML cell lines for the gilteritinib combination.